Physician profile
Hearn J Cho
NPI 1225060080
$42,898.09
in general payments reported to CMS, 2019-2025
18 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $504 · 2021: $4,273 · 2022: $728 · 2023: $8,512 · 2024: $5,801 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,740 · Travel and Lodging: $5,289 · Food and Beverage: $935 · Gift: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,740.00 |
| Travel and Lodging | $5,288.99 |
| Food and Beverage | $934.75 |
| Gift | $810.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19,745.43 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $7,996.37 | 2019-2023 | |
| F. Hoffmann-La Roche Ag | $6,077.91 | 2019-2024 | |
| Amgen INC. | $3,253.99 | 2020-2021 | |
| Glaxosmithkline, LLC. | $2,058.66 | 2019 | |
| Epizyme, INC. | $1,500.00 | 2021 | |
| Sekisui Diagnostics LLC | $1,160.00 | 2022-2025 | |
| American Orthodontics Corporation | $275.85 | 2019 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Janssen Biotech, INC. | $189.79 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Genentech, INC. | $149.43 | 2022 | |
| Janssen Research & Development, LLC | $129.70 | 2023 | |
| Pfizer INC. | $46.68 | 2025 | |
| Janssen Scientific Affairs, LLC | $27.34 | 2024 | Tecvayli, Talvey, Darzalex |
| Abbvie INC. | $22.84 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.14 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $13.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hearn Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.